prostate cancer
Conditions
Interventions
S-1 group:Androgen deprivation therapy
S-2 group:ADT plus bicalutamide
S-3 group:ADT plus second generation anti-androgens
R/I-1 group:ADT plus chemotherapy
R/I-2 group:ADT plus second generation anti-androgens
R/I-3 group:ADT and second generation anti-androgens plus chemotherapy
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult male newly diagnosed with mHSPC; 2. Histopathologic findings showed adenocarcinoma (including ductal adenocarcinoma and acinar adenocarcinoma); 3. There are enough tumor tissue specimens; 4. ECOG score 0 or 1; 5. Be willing to participate in the study and be able to comply with study requirements, including treatment and assessment of needs; 6. Sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Previously received endocrine therapy for primary prostate tumors. 2. Previous cytotoxic chemotherapy for prostate tumors. 3. Pathological findings showed that adenocarcinoma was accompanied by neuroendocrine small cell components. 4. Other malignancies are known to have progressed or require aggressive treatment. 5. Co-existing with other serious diseases, life expectancy < 12 months. 6. Have a history of dialysis or are currently on dialysis. 7. Currently participating or having participated in clinical trials studying reagents.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Time to Castration Resistant Prostate Cancer;PSA Complete Response at 6 Months;PSA Complete Response at 12 Months;Skeletal Related Events;Time to Opioid Use; | — |
Primary
| Measure | Time frame |
|---|---|
| Time to PSA Progression;Time to Radiographic Progression; | — |
Countries
China
Contacts
Public ContactWen Simeng
The Second Hospital of Tianjin Medical University
Outcome results
None listed